Meridian gets FDA clearance for new neonatal saliva CMV test

|About: Meridian Bioscience Inc. (VIVO)|By:, SA News Editor

Meridian Bioscience (NASDAQ:VIVO) has received FDA clearance for its new Alethia CMV Molecular Amplification Test (formerly, the illumigene brand).

This assay is designed to specifically detect congenital Cytomegalovirus (cCMV) infection in newborns from saliva sample.

Alethia CMV is the first qualitative test in a molecular amplification format, FDA-cleared for cCMV testing in newborns.

Subscribe for full text news in your inbox